Pituitary Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Pituitary Cancer Market Outlook

Thelansis’s “Pituitary Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pituitary Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pituitary Cancer Overview

Pituitary cancer arising from the anterior pituitary gland accounts for approximately 15% of intracranial neoplasms and is typically benign. However, these tumors may metastasize and be referred to as pituitary carcinoma in rare cases. The underlying etiology of pituitary gland tumors is not fully understood but likely involves genetic abnormalities and alterations. Hereditary conditions such as multiple endocrine neoplasias (MEN)-1 syndrome are associated with an increased risk of pituitary tumors. The pathophysiology of pituitary cancer is believed to be genetically related, but specific gene mutations have yet to be fully identified. Pituitary tumors may be functional, secreting hormones and causing particular symptoms, or non-functional, without hormone production. The clinical presentation of pituitary tumors can include symptoms related to the mass effect on surrounding structures, such as the optic chiasm or cavernous sinus. Surgery is the primary treatment for pituitary carcinoma and is estimated to have been performed on 80.5% of patients, with some undergoing multiple surgeries. Radiotherapy is also used in treating pituitary carcinoma, with an estimated 42.9% of patients receiving at least two courses. Conformal radiotherapy, which aims to provide both antitumoral and antisecretory effects, can be considered, but data on its efficacy is limited. Chemotherapy, specifically with the oral alkylating agent temozolomide, is also used in treating pituitary carcinoma and has improved progression-free and overall survival rates. Antisecretory medications, such as dopamine agonists, steroidogenesis inhibitors, and somatostatin analogues, are also crucial in controlling pituitary hormone hypersecretion in patients with pituitary carcinoma.

• The incidence of Pituitary cancer ranges from 3.9 to 7.4 cases per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: